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Abstract Evidence is presented that the growth factor glycyl- 
histidyl-lysine (GHK) binds to heparin, and the interaction has 
been characterized by [1HINMR spectroscopy. ~H chemical shifts 
indicate that GHK interacts with both the carboxylic acid and the 
carboxylate forms of heparin. The chemical shift data are con- 
sistent with a weak delocalized binding of the triprotonated 
(ImH ÷, GIyNH~, LysNH~) form of GHK by the carboxylic 
acid form of heparin. As the pD is increased and the carboxylic 
acid groups are titrated, chemical shift data indicate that ammo- 
nium groups of GHK are hydrogen bonded to heparin carboxylate 
groups, while the histidyl imidazolium ring occupies the imi- 
dazolium-binding site of heparin. Evidence for site-specific bind- 
ing includes displacement of chemical shift titration curves for 
heparin to lower pD, increased shielding of specific heparin pro- 
tons by the imidazolium ring current and displacement of chemi- 
cal shift titration curves for GHK to higher pD. Specific binding 
constants were determined for binding of the (ImH ÷, GIyNH~), 
LysNH~), (ImH ÷, GlyNH 2, LysNH~) and (Im, GIyNH~, 
LysNH~) forms of GHK by the carboxylate form of heparin 
from chemical shift vs. pD titration data. 
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1. Introduction 
The tripeptide growth factor glycyl-L-histidyl-L-lysine 
(GHK) was first isolated from human plasma in 1973 [1]. Since 
then, it has been shown to have a wide range of biological 
activities [2]. GHK stimulates the growth or enhances the via- 
bility of several types of cultured cells and organisms, including 
neuronal cells [3,4], lymphocytes [5], hepatocytes [1,6], Ascaris 
suum and Litomosoides carnii larvae [7,9], and the human 
tumor cell lines KB and HeLa [10]. GHK is a chemoattractant 
for capillary endothelial cells and mast cells [2,11,12]. Rapidly 
growing cells produce GHK or a similar peptide, and recent 
work suggests a role for GHK or its copper complex (GHK- 
Cu) in the processes of wound healing and tissue repair [2]. 
GHK-Cu accelerates the healing or closure of superficial 
wounds in rats, pigs and mice [2], and stimulates the accumula- 
tion of connective tissue in rat wounds [13,14]. 
Even though GHK and its copper complex have a wide range 
of biological activity, little is known about heir specific interac- 
tions with biological macromolecules. Many polypeptide cy- 
tokines, including peptide growth factors, bind to the glycosam- 
inoglycan heparin [15], and presumably to the closely related 
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heparan sulfate part of cell surface heparan sulfate proteogly- 
cans. In heparan sulfate, there are approximately equal num- 
bers of N-sulfated and N-acetylated glucosamine residues, ar- 
ranged predominantly in segregated 'block-wise' distributions 
[15,16]. Thus, heparin is considered to be a valid functional 
analog for binding to the heparin-like segments of heparan 
sulfate [16]. 
In this paper, we report hat GHK binds to the glycosamin- 
oglycan heparin; the binding interaction has been characterized 
by [IH]NMR spectroscopy and is shown to involve the N- 
terminal glycyl ammonium, the histidyl imidazolium and the 
lysine ammonium groups, with the imidazolium group interact- 
ing site specifically with the imidazolium-binding site on hepa- 
rin [17]. 
2. Materials and methods 
Beef lung heparin (sodium salt) (153 USP U/mg, 1~17 kDa) and 
glycyl-histidyl-lysine w re obtained from Sigma. NMR measurements 
were made on D20 solutions containing heparin, GHK and heparin 
plus GHK. Heparin concentrations are expressed in terms of the con- 
centration of the repeating disaccharide unit. Solution pD was adjusted 
with concentrated solutions of DC1 and NaOD in D20. pD was meas- 
ured using microcombination electrodes whose response was calibrated 
with certified standard buffer solutions; pH meter eadings were con- 
verted to pD using the equation pD = prime t . . . . .  ding + 0.40 [18]. 
[~H]NMR spectra were measured at 500 MHz and 37°C with a 
Varian VXR-500S NMR spectrometer. The residual HOD resonance 
was suppressed by selective presaturation for1 2 s. before application 
of the non-selective observation pulse. ~H chemical shifts were meas- 
ured relative to the resonance for the methyl protons of internal t-butyl 
alcohol (6 = 1.2365 ppm) or 2,2-dimethyl-2-silapentane-5-sulfonate 
(DSS, 6 = 0.0 ppm). 
Non-linear least squares calculations were done with the program 
Scientist from MicroMath Scientific Software. 
3. Results and discussion 
Heparin is a negatively charged polysaccharide, comprised 
largely of repeating sequences of the trisulfated isaccharide 
{(1--* 4)-2-O-sulfo-ct-e-idopyranosyluronic acid-(1 ---~ 4)-2-deoxy- 
2-sulfamido-6- O sulfo-ct-D-glucopyranose } or (IdoA-2S)- 
(1---~4)-(GIcNSO3-6S), shown below with the iduronic acid res- 
idue (the I ring) in the ~C4 conformation and the glucosamine 
(the A ring) in the 4C t conformation. Because of its high nega- 
tive charge density, many biological molecules, including hista- 
mine and many peptides and proteins [15,17], bind to heparin. 
The binding mechanism ay be either delocalized (territorial) 
or site specific electrostatic interactions between anionic sites 
on heparin and cationic sites on the biological molecules [15]. 
The growth factor glycyl-histidyl-lysine has three potential 
sites for interaction with heparin: the glycyl ammonium group, 
the histidyl imidazolium group and the lysine ammonium 
group. Evidence for the binding of GHK by heparin was 
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Scheme 1. 
obtained from tH chemical shift data measured as a function 
of pD for heparin, the peptide and heparin plus peptide. 
Chemical shift vs. pD data for the I5 and A3 protons of 
heparin are presented in Fig. 1 for free heparin and for heparin 
plus GHK at a 2.7 : 1 ratio. Chemical shift data are presented 
in Fig. 2 for the glycyl CH2 and histidyl C2H protons and in 
Fig. 3 for the lysine e-CH 2 protons of free GHK and of GHK 
plus heparin. The 2.8-5.5 ppm portion of representative spectra 
of solutions containing GHK plus heparin, with the resonances 
plotted in Figs. 1-3 identified, are presented in Fig. 4. The data 
in Figs. 1-3 establish that heparin binds GHK, that exchange 
of both GHK and heparin between their free and bound states 
is fast on the NMR time scale, and that the nature of the 
binding interaction is pD-dependent. Displacement of reso- 
nances for the Hep-A3, His-C2H, Gly-CH2 and Lys E-CH2 
protons at low pD indicates binding, presumably by non-spe- 
cific electrostatic interactions between GHK and anionic sites 
on heparin. As the pD is increased over the range of 3-7 and 
the carboxylic acid group of the iduronic acid residue is titrated, 
the I5 resonance for free heparin (curve C in Fig. 1) shifts 
upfield; a pK A of 5.49 + 0.04 was obtained from the I5 chemical 
shift vs. pD data for free heparin. An apparent pK A of 
4.70 + 0.03 was obtained from the data in the presence of GHK 
(curve D in Fig. 1). Displacement of the Hep-I5 chemical shift 
titration curve to lower pD indicates a specific interaction be- 
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Fig. 1. Chemical shifts of resonances for the A3 and I5 protons of 
heparin as a function of pD; assignments are given on the structural 
formula of heparin. Curves A and C are for 12.3 mM sodium hepari- 
nate; curves B and D are for a solution of 13.7 mM sodium hepari- 
nate+5.1 mM GHK. Both solutions contain ~50 mM Na ÷ 
from the sodium heparinate. 
tween the heparin carboxylate sites and GHK, as described by 
the following equilibria: 
HepCO2H ~ HepCO~ + H ÷ (1) 
HepCO~ + H3 A2+ ~ HepCO2 - Ta,13A 2+ (2) 
where H3 A2+ represents the triprotonated (ImH ÷, GlyNH;, 
LysNH~) form of GHK. Formation of the HepCO~-H3A 2+ 
complex has the effect of shifting the deprotonation equilibrium 
to the right. 
The A3 resonance for free heparin (curve A) also shows a 
small change in chemical shift when the heparin carboxylic acid 
group is titrated due to a change in conformation across the 
(GlcNSO3-6S)-(1--)4)-(IdoA-2S) glycosidic bond [17]. In the 
presence of GHK, the A3 resonance is displaced upfield over 
the entire pD range of 2-10, with the maximum displacement 
being -0.16 ppm at pD 6. Other A ring resonances also shift 
upfield but the shifts are smaller (0.03 and 0.04 ppm for the AI 
and A4 resonances at pD 6). The displacement of the A3 reso- 
nance is consistent with site-specific binding of the imidazolium 
group to a binding site in which the imidazolium ring is located 
above the A3 proton [17], causing the A3 resonance to be 
shifted upfield by ring current effects [19]. 
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As the pD is increased from 4 to 10, the imidazolium and 
glycyl ammonium groups are titrated and resonances for the 
His-C2H and Gly-CH2 protons hift upfield. In the presence of 
heparin, the chemical shift titration curves for both are dis- 
placed to higher pD. Displacement of the His-C2H chemical 
shift titration curve to higher pD provides further evidence for 
participation of the imidazolium group in heparin-GHK bind- 
ing, while the shift of the Hep-A3 resonance back to the chem- 
ical shift of free heparin upon titration of the imidazolium 
group indicates that only the imidazolium form of the histidyl 
side-chain is involved in binding. The His-C2H and Gly-CH2 
chemical shift titration curves together with displacement of the 
Lys e-CH2 resonance to lower field (Fig. 3) indicate that the 
imidazolium, glycyl ammonium and lysine ammonium groups 
are all involved in binding to heparin at pD 6. 
At pD -> 10, the chemical shifts of the Hep-A3, His-C2H, 
Gly-CH 2 and Lys &CH 2 resonances are the same for solutions 
containing heparin, GHK and heparin plus GHK, indicating 
that, even though the lysine side-chain is protonated at pD 10, 
the (Im, GlyNH2, LysNH~) form of GHK does not bind to 
heparin. 
Similar chemical shift titration data were obtained for solu- 
tions which contained heparin and GHK at ~ 5 : 1 ratio (12.3 mM 
heparin, 2.6 mM GHK and ~50 mM Na + from the sodium 
heparinate) whereas the displacement of the His-C2H and GIy- 
CH~ titration curves to higher pD was somewhat less when 
solutions also contained 0.15 M NaC1. The dependence on 
NaCI concentration i dicates that binding of GHK involves 
displacement of Na ÷ ions from the polyelectrolyte counterion 
condensation volume [20] around heparin. 
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Fig. 3. Chemical shift of the resonance for the Lys e-CH2 proton of 
GHK as a function ofpD. Curve A is for 2.6 mM GHK; curve B is for 
13.7 mM sodium heparinate + 5.1 mM GHK. 
The acid/base and heparin-binding equilibria of GHK are 
summarized in Fig. 5. The chemical shift data in Fig. 2 indicate 
that the imidazolium and glycyl ammonium groups of the 
(ImH ÷, GlyNH~, LysNH~) form of GHK (species A in Fig. 5) 
are of similar acidity and deprotonate o give either species B 
or C, which then deprotonate to give species D [21]. Micro- 
scopic acid dissociation constants were calculated by fitting the 
His-C2H and Gly-CH2 chemical shift data for free GHK in Fig. 
2 to Eqns. 3 and 4. 
~C2H = 0CA "t- fc )  6C2H,ImH "t- (fB "t- fD) I~C2H,Im (3) 
~Gly ---- (fA q- fB) 6Gly, NH 3 "k" (fc "]" fD) ~GIy, NH 2 (4) 
where ~C2H is the observed chemical shift of the His-C2H pro- 
ton and fiC2H,]mH and ~c2H.~m the chemical shifts of the His-C2H 
proton when the histidine side-chain is in the imidazolium and 
imidazole forms. ~ty, ~Gly, NH3 and ~GIy, NH2 are defined analo- 
gously for the glycine methylene protons, fA-fD are the frac- 
tional concentrations of species A-D, as defined in Fig. 5. 
fA = [H+]2/Denom,fB = [H+]k]/Denom,fc = [H+]kJDenom and 
fD = k lk JDenom, where Denom= [H+] 2 + [H+]kl + [H+]k2 + 
k~k]2. Values of pkl = 6.70, pk 2 = 7.81, pk12-- 8.16 and 
pk2] = 7.04 were obtained by fitting simultaneously chemical 
shift data for the His-C2H and GIy-CH2 protons by non-linear 
least squares methods to Eqns. 3 and 4. The solid curves 
through data sets A and C in Fig. 2 are theoretical curves 
predicted using these pk values. 
The chemical shift data also indicate that GHK species A-C 
in Fig. 4 interact with heparin. The length of heparin polymer 
which binds GHK is not known, however, molecular models 
suggest a tetrasaccharide segment would accomodate one mol- 
ecule of GHK. Binding constants defined in terms of heparin 
tetrasaccharide-binding units were estimated by fitting the ob- 
served chemical shift data for the His-C2H and GIy-CH 2 pro- 
tons in the presence of heparin to Eqns. 5 and 6. 
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Fig. 4. Portions of the 500 MHz [~H]NMR spectra of a solution which 
contained 13.7 mM sodium heparinate + 5.1 mM GHK at pD values 
of (A) 3.93, (B) 6.32, (C) 8.45 and (D) 10.44. 
6C2H = 0(A Jr fC)aC2H,ImH + 0CB Jr fD Jr fHep-B)~C2H,Im Jr 
(fHep-A Jr fHep-C)aC2H,Bound (s) 
~Gly --~ 0gA Jr fB)6GIy,NH 3 Jr (/'C Jr UD Jr fHep-C)6GIy, NH 2 Jr 
(fHep-A Jr/Hep-B)(~Gly, Bound (6) 
where ~C2H is the observed chemical shift of the His-C2H pro- 
ton, ~C2H,ImH and ~C2U,lm are defined as for Eqn. 3 and ~C2H,Bound 
is the chemical shift of the C2H proton of the bound histidine 
side-chain in the imidizolium form. ~61y, L;61y, NH3, 6GIy.NH2 and 
(~Gly, Bound are defined analogously for the glycine methylene pro- 
tons. fA,fB, etc., the fractional concentrations of the subscripted 
species defined in Fig. 5, were expressed in terms of the micro- 
scopic acid dissociation constants, the binding constants and 
the concentrations of GHK and heparin tetrasaccharide. Val- 
ues of Kfl =12,700-+300 M, Kn=250+20 M, and 
Kf3 -- 300 + 90 M were estimated for the binding constants by 
fitting simultaneously data sets B and D in Fig. 2 to Eqns. 5 
and 6. Binding constants of Kfl = 36,500 + 1300 M, 
Kr2 -- 480 _+ 30 M and Kf3 -- 500 _+ 150 M were estimated using 
data sets analogous to B and D in Fig. 2 for 2.6 mM GHK plus 
12.3 mM heparin disaccharide. The decrease in binding con- 
stant as the heparin to peptide ratio decreases indicates antico- 
operativity in the binding of GHK. The solid curves through 
data sets B and D in Fig. 2 are theoretical curves calculated 
using the microscopic acid dissociation constants and the bind- 
ing constants estimated from these data sets. The distribution 
of GHK among its various protonated and heparin-bound spe- 
cies is shown as a function of pD in Fig. 6. 
3.1. Conclusions 
The chemical shift data presented in Figs. 1-3 establish that 
the growth factor GHK can bind to heparin, and presumably 
also to the heparin-like [(IdoA-2S)-(1--+4)-GIcNSO3-6S)], se- 
quences of cell surface heparan sulfate proteoglycans [15,16]. 
The nature of the heparin-GHK binding interaction is pH- 
dependent. At low pH, where the heparin carboxylate group is 
protonated, the binding involves delocalized electrostatic inter- 
actions between cationic GHK and anionic heparin. At physio- 
logical pH, the imidazolium side-chains of the (ImH +, GIyNH~, 
LysNH~) form of GHK bind site specifically to imidazolium- 
binding sites on heparin, while the ammonium groups interact 
with heparin carboxylate groups. The species distribution dia- 
gram in Fig. 6 shows that the extent and nature of the binding 
are sensitive to pH, with a significant amount of heparin bind- 
ing to the (ImH ÷, GlyNH~, LysNH~) and (Im, GlyNH~, 
LysNH~) forms of GHK at physiological pH. 
The basic side-chains of lysine and arginine are generally 
assumed to be the sites of heparin and heparan sulfate binding 
to proteins [22], although it has been suggested that the histid- 
ine side-chains of several peptides and proteins, including syn- 
thetic fl-amyloid peptides [23], histidine-rich glycoprotein [24] 
and platelet factor 4 [25], bind to heparin. The results presented 
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Fig. 5. Microscopic acid dissociation and heparin-binding scheme for 
GHK. 
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Fig. 6. Species distribution of GHK in a solution containing total 
peptide and heparin concentrations of 5.1 mM and 13.7 mM, respec- 
tively. The species are defined in Fig. 5. The distribution curves were 
calculated using equations which express the fractional concentrations 
in terms of the microscopic acid dissociation constants, the binding 
constants (Kf~ = 12,700, Kf2 = 250 and Kf3 = 300) and the concentration 
of peptide and heparin. 
here provide direct experimental evidence for heparin-histidine 
side-chain binding. 
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